StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.02−1.35 (-2.58%)

Close on Nov 16, 2026Market cap $1.52BP/E –Yield –

GeneDx gross margin

Gross margin is gross profit as a percentage of revenue.

GeneDx's gross margin for the twelve months ending Jun 30, 2026 was 69.4%. For fiscal 2025 it was 69.7%, against 63.6% the year before. The highest annual figure on record is 69.7% in fiscal 2025.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202569.7%+6.1
FY2024Dec 31, 202463.6%+19.2
FY2023Dec 31, 202344.4%+55.8
FY2022Dec 31, 2022-11.4%−3.6
FY2021Dec 31, 2021-7.8%−10.1
FY2020Dec 31, 20202.2%−40.0
FY2019Dec 31, 201942.2%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202668.4%−0.7
Q1 FY2026Mar 31, 202666.7%−0.4
Q4 FY2025Dec 31, 202569.6%+0.4
Q3 FY2025Sep 30, 202572.4%+10.2
Q2 FY2025Jun 30, 202569.0%+8.1
Q1 FY2025Mar 31, 202567.1%+7.2
Q4 FY2024Dec 31, 202469.2%+15.7
Q3 FY2024Sep 30, 202462.2%+14.8
Q2 FY2024Jun 30, 202460.9%+22.4
Q1 FY2024Mar 31, 202459.9%+24.6
Q4 FY2023Dec 31, 202353.6%+80.2
Q3 FY2023Sep 30, 202347.4%+31.1
Q2 FY2023Jun 30, 202338.5%+120.3
Q1 FY2023Mar 31, 202335.3%+24.9
Q4 FY2022Dec 31, 2022-26.6%−21.8
Q3 FY2022Sep 30, 202216.3%+35.5
Q2 FY2022Jun 30, 2022-81.8%−79.4
Q1 FY2022Mar 31, 202210.4%+17.2
Q4 FY2021Dec 31, 2021-4.9%+4.0
Q3 FY2021Sep 30, 2021-19.2%−31.1
Q2 FY2021Jun 30, 2021-2.5%+12.2
Q1 FY2021Mar 31, 2021-6.7%−27.1
Q4 FY2020Dec 31, 2020-8.9%–
Q3 FY2020Sep 30, 202011.9%–
Q2 FY2020Jun 30, 2020-14.6%–
Q1 FY2020Mar 31, 202020.4%–

More GeneDx figures

See a number that looks wrong?